Canopy Growth Is Closing in on Positive EBITDA. Should You Buy the Stock?

Key Points Positive adjusted EBITDA could mark an important turnaround milestone. Sustained revenue growth could strengthen Canopy’s investment case. Free cash flow remains a major concern for investors. 10 stocks we like better than Canopy Growth › Canopy Growth (NASDAQ: CGC) is getting closer to something marijuana investors have been waiting years to see: positive adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization). The Canada-based cannabis company recently reported Q1 fiscal 2027 net revenue of about $57.4 million, up 13% year over year, with growth across every major business. Cannabis revenue increased 14%, and growth wasn't limited to one market. Canadian medical cannabis revenue jumped 22% to about $18.